

Clinical severity in adult warm autoimmune hemolytic anemia and its relationship to antibody specificity

Warm autoimmune hemolytic anemia (wAIHA) is a rare autoantibody (autoAb)-mediated immune disorder that affects both children and adults.¹⁻³ The pathology of the disease is caused by immunoglobulin G (IgG)-, IgM-, or IgA-type autoAbs associated, or not, with molecules of the complement system, and directed against self-erythrocytes. Red blood cell (RBC) destruction is induced by activation of FcγR-bearing effector cells, mainly in the spleen after sequestration and trapping by splenic macrophages.^{4,6} The most common RBC-antigen targets in wAIHA are major RBC membrane proteins, but few studies have investigated the clinical or biological relevance of such specificities,^{7,8} even though anti-Band 3 Abs have long been postulated to induce more severe hemolysis.⁹

In the present study, we determined the specificity of Ig autoAbs of wAIHA and explored whether there is a correlation between the specificity of the three-main autoAbs against membrane RBC proteins and the severity of the disease in a cohort of wAIHA patients. We also investigated the functional properties of eluted autoAbs using functional *in vitro* assays. We prospectively explored 52 samples sequentially obtained from 40 patients (24 women/16 men, mean age: 56 years [range: 21-98]) treated for AIHA in the French National Referral Center for adult immune cytopenias. Twenty-seven patients had primary wAIHA and 13 had secondary. Samples were obtained either recently after diagnosis (n=10), during (n=9), or after treatment (n=33). A full description of the cohort and of the methods are described in *Online Supplementary Material*. Investigations of patient RBCs included the direct antiglobulin test (DAT), antibody screening tests, and searches for antibodies in serum. IgM-type antibodies were never found alone on patient RBCs, but were mixed with other Abs in eight samples (15.4%, sequentially collected from four patients). Three patient samples (5.8%) were C3d positive alone, and the DAT was negative for four (7.7%). We found IgA autoAbs (always mixed with IgG) in seven patients (see also *Online Supplementary Table S1*). We tested the autoAbs obtained from the 29 patients with a pro-

active DAT (*Online Supplementary Table S2*). Antibody specificities, deduced from negative reactions with specific antigen-null RBCs,^{5,10} were Rhesus (RH) for 11 patients (monospecific for six), Band 3 for eight (monospecific for six), Glycophorin A (GPA) for seven (no monospecific), and unknown for three. Analysis of the patient samples sequentially collected during the follow up resulted in no significant changes in Ab specificity and only slight changes of the Ig-type classes and sub-classes (data not shown). We performed acidic elution of the autoAbs from patient RBCs. Thirty-five percent of the eluates contained several classes and sub-classes of antibodies. Forty-four samples (84.6%) contained IgG-type antibodies, mainly the IgG1 isotype (n=36; 69.2%), either alone (n=18; 34.6%) or mixed with other Abs, in contrast to IgG3 (n=8, 15.4%), which was always mixed with IgG1. The autoAbs demonstrated a large thermic range (as titers were similar when tested at +37°C or +20°C), and the titers were from 0 to 1024. Eluates were diluted to a final titer of between 8 and 128 for further studies; eluates with very low autoAbs titers (titer < 8) were excluded from subsequent investigations (11/52 eluates).

We first compared the relative clinical management of the patients as a function of autoAb specificity, assessed by immuno-hematological testing (*Online Supplementary Table S2*). There were no significant differences between the three autoAb specificity categories, nor for the three unknown eluate specificities, among the 29 patients, based on hemoglobin (Hb) levels at the time of diagnosis, the nadir of Hb counts during the course of the disease, or the number of lines of therapy, which is an indirect marker of the severity of wAIHA (Figure 1).

We conclude that specificity against RBC membrane antigens is not associated with the severity of the disease. Phagocytosis of autoAb coated RBCs in wAIHA may be the principal pathogenic mechanism underlying RBC destruction, except under certain conditions in which macrophages simply remove clusters of cell-bound IgG on RBCs coated with autoAbs; this phenomenon is called "antigen-shaving" or trogocytosis.^{11,12} The testing of phagocytic reactivity of monocytes *in vitro* with Ab-coated RBCs is a useful parameter for evaluating *in vivo* immune RBC destruction in the diagnosis of AIHA or evaluation of the patient response to treatment.¹⁵ For this test, normal adherent monocytes were overlaid onto RBCs, sensitized, or not, with eluted autoAbs and incubated for 2 hours at 37°C. Slides were then observed




Figure 1. Parameters for clinical management of AIHA patients from the cohort as a function of autoAb specificity based on the results obtained from *in vitro* cellular investigations. Clinical management of the patients as a function of autoAb specificity. Hb levels of patients at the time of diagnosis (on the left), the nadir of Hb (in the center), and the number of lines of therapy (on the right) are indicated and represented as Boxes/Whiskers (min to max values); the horizontal bar in each box indicates the median. GPA: Glycophorin A; RH: Rhesus.

In a previous study, we used a polyspecific Fc-Blocker to confirm the lack of involvement of Fc-receptors (FcR) in monocyte-mediated trogocytosis by Ig autoAbs.⁴ We quantified the effect of the Fc-Blocker as well as that of anti-Fc γ RI/CD64 and anti-Fc γ RIII/CD16 mAbs on the autoAb-induced erythro-trogocytosis by monocytes (*Online Supplementary Figure S2A, S2B*). AutoAb-activated CD14⁺ trogocytosis was markedly reduced by pre-incubation of the monocytes with the Fc-Blocker (Figure 3C; see also *Online Supplementary Figure S1C* for the representation of the inhibition index obtained for each specificity). Nevertheless, RBC trogocytosis was not totally abolished by a pan Fc-blocking mixture, with persistent intracellular PKH-67 staining detected in CD14⁺ monocytes (Figure 3D); we also observed this result using higher concentrations of the pan Fc-Blocker (five-fold tested; *data not shown*).⁴ This suggests that RBC membrane transfer to monocytes might contribute to RBC destruction by a mechanism other than classical Fc-mediated phagocytosis because intracellular RBC components were still observed after Fc-Blocker pretreatment. It has been shown that SIRP α also plays a role in the removal of aged RBCs through CD47 binding.¹⁴ The exact mechanism explaining this observation remains to be investigated.

We also assessed antibody-dependent cell-mediated cytotoxicity (ADCC) of PBMC subsets towards sensitized-RBCs through degranulation using transient CD107a exposure at their cell surface.¹⁵ Only very low levels of CD107a staining were detected on CD3⁺CD16/56⁺ natural killer (NK) cells for most of the autoAbs tested (n=25). We also assessed ADCC of CD3⁺CD16/56⁺ natural killer T (NKT) cells and CD3⁺/CD8⁺ T cells, which was negative (*data not shown*). Most values obtained for NK cells were just above or below the estimated baseline cutoff (*Online Supplementary Figure S3A*). Two autoAbs induced weak CD107a MFI in NK cells and two others (one specific to GPA, the other to Band 3) triggered modest ADCC activity (above the baseline cutoff) for NK immune effector cells. Thus, the wAIHA autoAbs tested only weakly triggered the cytotoxic process of immune effector cells. Again, there was no correlation between Hb levels and ADCC ($R^2=0.0236$; $P=0.4630$; *Online Supplementary Figure S3B*).

Taken together, our data demonstrate that the ability of anti-RBC AutoAbs to induce either phagocytosis, trogocytosis, and to a lesser extent, ADCC in wAIHA is not related to their antigen specificity. They also suggest that




Figure 3. CD14⁺-mediated trogocytosis and blocking with anti-Fc γ R blocking antibodies or a polyspecific Fc Blocker, with autoAb-coated RBCs. For erythro-trogocytosis experiments, PKH-67-labeled normal RBCs were incubated with PBMCs for 60 min. Spontaneous directed membrane transfer between RBCs and the gated CD14⁺ monocyte population was quantified before (T0 min) and after coculture (T60 min), visualized as the acquisition of PKH-67 fluorescence by CD14⁺ monocytes for 60 min; monoclonal IgG anti-RhD served as positive control. Data were collected on a BD Canto 2 flow cytometer. Values of the MFI of gated populations is indicated. Similar results were obtained in at least two other experiments. (B) Results for the erythro-trogocytosis index visualized in monocytes as the ratio (PKH-67 CD14⁺ MFI for eluate-sensitized RBCs)/ (PKH-67 CD14⁺ MFI for non-coated RBCs). Results are shown as the means \pm SD from at least three independent experiments; the horizontal bar in each box indicates the median. (C) Results for erythro-trogocytosis obtained by flow cytometry and expressed as raw data (PKH-67 CD14⁺ MFI) with normal RBCs sensitized with the eluted autoAbs and then incubated for 60 min with monocytes treated or not with the pan Fc-Blocker. Results are from at least three independent experiments and represented as Boxes/Whiskers (min to max values); the horizontal bar in each box indicates the median. Results were only significant for specificity for GPA ($P=0.0358$; ANOVA with the Kruskal-Wallis multiple comparison test). (D) Fluorescence microscopy results for erythro-trogocytosis results by fluorescence microscopy with RBCs sensitized or not with the eluted autoAbs and then incubated with monocytes. Results for an anti-GPA eluate and an anti-RH eluate are shown from one representative experiment. Normal RBC membranes were stained with the lipophilic dye PKH-67 (green); PBMCs were loaded with CMTMR (orange) to visualize the cytoplasm of nucleated cells. RBCs and PMBS were then incubated together for 60 min at +37 °C. The monocytes were then stained with Alexa-Fluor (AF)-647 coupled (red) mIgG anti-CD14 and mounted with a DAPI-containing mounting medium. Data were collected on a Zeiss Observer Z1 microscope and analyzed using Zen software. GPA: Glycophorin A; RH: Rhesus.

clinical severity may be dependent on the functional activity of the anti-RBC antibodies. Further studies are needed to investigate the activation state of the patients' immune cells, which control the level of RBC destruction by phagocytosis and erythro-trogocytosis, as a part of the complex pathogenesis of the disease.

Philippe Chadebech,^{1*} Valentine Loustau,^{1,2*} Daniel Janvier,³ Laetitia Languille,² Julie Ripa,² Marie Tamagne,¹ Philippe Bierling,^{1,2} Rachid Djoudi,⁴ Bertrand Godeau,² Marc Michel,² France Pirenne^{1,5*} and Matthieu Mahévas^{1,2*}

¹Etablissement Français du Sang, Île-de-France, Hôpital Henri-Mondor, Créteil; INSERM U955 équipe 2: Transfusion et Maladies du Globule Rouge; IMRB (Institut Mondor de Recherche Biomédicale), Créteil; laboratoire d'Excellence GR-Ex, F75739 Paris;

²Service de Médecine Interne, Centre de Référence des Cytopenies Auto-Immunes de l'Adulte, GECAL, Hôpital Henri-Mondor, AP-HP, UPEC, Créteil; ³Etablissement Français du Sang, Île-de-France, Hôpital Saint-Louis, Paris; ⁴Etablissement Français du Sang, Île-de-France, Ivry-sur-Seine and ⁵UPEC, Université Paris-Est-Créteil Val-de-Marne, Créteil, France

*PC and VL contributed equally to this work.

Acknowledgments: we particularly thank Sadaf Pakdaman and Jennifer Martret for their rigorous collection and banking of the patient samples in the cohort. We also thank Prof. Yves Beuzard for constructive discussions and careful reading of the manuscript.

Funding: this work was supported by the Comité Scientifique of the EFS (Etablissement Français du Sang) and by the SNFMI (Société Nationale Française de Médecine Interne)

Correspondence: france.pirenne@efs.sante.fr
doi:10.3324/haematol.2017.175976

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References

- Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. *Haematologica*. 2014;99(10):1547-1554.
- Crowther M, Chan YLT, Garbett IK, et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. *Blood*. 2011;118(15):4036-4040.
- Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. *Am J Hematol*. 2014;89(9):150-155.
- Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. *Expert Rev Hematol*. 2011;4(6):607-618.
- Chadebech P, Michel M, Janvier D, et al. IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and Fc α RI. *Blood*. 2010;116(20):4141-4147.
- Mahévas M, Michel M, Vingert B et al. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm autoimmune hemolytic anemia patients treated with rituximab. *J Autoimmun*. 2015;62:22-30.
- Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood*. 2014;124(19):2930-2936.
- Lai M, De Stefano V, Landolfi R. Haemoglobin levels in autoimmune hemolytic anaemias at diagnosis: relationship with immunoproteins on red blood cells. *Immunol Res*. 2014;60(1):127-131.
- Brain MC, Prevost JM, Pihl CE, Brown CB. Glycophorin A-mediated haemolysis of normal human erythrocytes: evidence for antigen aggregation in the pathogenesis of immune haemolysis. *Br J Haematol*. 2002;118(3):899-908.
- Janvier D, Sellami F, Missud F, et al. Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1). *Transfusion*. 2002;42(12):1547-52.
- Poupot M, Fournie JJ. Spontaneous membrane transfer through homotypic synapses between lymphoma cells. *J Immunol*. 2003; 171(5):2517-2523.
- Pham T, Mero P, Booth JW. Dynamics of macrophage trogocytosis of rituximab-coated B cells. *PLoS One*. 2011;6(1):e14498
- Biondi CS, Cotorruelo CM, Ensinn A, et al. Use of the erythrophagocytosis assay for predicting the clinical consequences of immune blood cell destruction. *Clin Lab*. 2004;50(5-6):265-270.
- Burger P, Hilarius-Stokman P, de Korte D, et al. CD47 functions as a molecular switch for erythrocyte phagocytosis. *Blood*. 2012;119(23):5512-5521.
- Aktas E, Kucuksezer UC, Bilgic S, et al. Relationship between CD107a expression and cytotoxic activity. *Cell Immunol*. 2009; 254(2):149-154.